Rybelsus treatment: the semaglutide pill for diabetes

My articles

Rybelsus treatment: the semaglutide pill for type 2 diabetes, weight and heart protection

By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv

What is Rybelsus treatment, and who is it for?

Rybelsus treatment delivers semaglutide as a daily pill, with no injection. It is the same active ingredient found in Ozempic and Wegovy. The United States approved the drug in 2019, and Europe followed in 2020, to control type 2 diabetes. Since then, new data have accumulated: heart protection, an improved formulation and a new sister drug for obesity. So it is time to update the picture.

It is important to be precise from the start. Regulators approved Rybelsus for people with type 2 diabetes, not as an obesity drug. Still, weight loss is part of its effect. If you are looking for a pill for obesity alone, you can read about the Wegovy pill for weight loss, which the FDA approved at the end of 2025.

How Rybelsus works in the body

Semaglutide mimics the hormone GLP-1, a satiety hormone that the gut releases after a meal. This hormone increases insulin release only when blood sugar is high. In addition, it lowers glucagon release, slows stomach emptying and acts on the fullness centers in the brain.

The big challenge was getting a protein like this through the digestive system. The solution is a carrier substance called SNAC. It protects the drug in the stomach and lets the stomach wall absorb it. Because of this mechanism, the way you take the pill strongly affects how well it works.

What the PIONEER trials showed

The PIONEER research program tested Rybelsus in patients with type 2 diabetes. The PIONEER 1 trial included 703 patients for 26 weeks. At the 14 mg dose, HbA1c (average blood sugar over the past three months) fell by 1.1% more than with placebo. Weight fell by 2.3 kg more than with placebo.

The PIONEER 4 trial compared the pill with liraglutide injections. After 26 weeks, HbA1c fell by 1.2% with Rybelsus, compared with 1.1% with the injection. In addition, weight loss with the pill was 4.4 kg, more than with liraglutide. In other words, the pill held its own against an established daily injection.

Rybelsus treatment and the heart: the SOUL trial

The most important change came in 2025. The SOUL trial included 9,650 patients aged 50 or older with type 2 diabetes. All of them had cardiovascular disease, chronic kidney disease or both. The trial compared Rybelsus 14 mg with placebo, on top of usual care.

A major cardiac event (cardiovascular death, heart attack or stroke) occurred in 12.0% of patients on Rybelsus. By comparison, such an event occurred in 13.8% of the placebo group. This is a 14% relative reduction in risk. Most of the benefit came from fewer non-fatal heart attacks.

Following these results, the U.S. Food and Drug Administration (FDA) approved Rybelsus in October 2025 for cardiovascular risk reduction as well. This made Rybelsus the first GLP-1 pill with proven heart protection. You can read more about the mechanism in my article on semaglutide and the heart.

Rybelsus and weight loss: what to expect

Weight loss with Rybelsus is moderate compared with dedicated obesity drugs. The reason is simple: the doses aim at blood sugar control, not at obesity. For example, in PIONEER 1 the difference from placebo was 2.3 kg over six months. That said, some patients lose more, especially when they combine the drug with diet and exercise.

Therefore, when the main goal is weight loss, Rybelsus is usually not the first choice. In such cases, we consider a dedicated obesity treatment, as an injection or a pill.

Rybelsus or the Wegovy pill?

The Wegovy pill also contains semaglutide, but at a dose of 25 mg. The OASIS 4 trial included 307 adults with overweight or obesity, without diabetes. After 64 weeks, participants lost an average of 13.6% of their body weight, compared with 2.2% on placebo. In other words, it is a different drug with a different goal. A detailed comparison with another pill appears in my article on Foundayo vs oral semaglutide.

A new formulation and updated doses

At the end of 2025, a new formulation began to replace Rybelsus tablets. The new tablets are small and round, and the body absorbs them much better. As a result, the doses changed: 1.5 mg instead of 3 mg, 4 mg instead of 7 mg, and 9 mg instead of 14 mg. Effectiveness and safety are the same.

In the United States, Novo Nordisk has sold the new tablets under the Ozempic name (the Ozempic pill) since May 2026, and it is keeping the Rybelsus name outside the U.S. It is the same drug in the same doses.

The UK medicines regulator warned about medication errors during the transition, while both types are on the market. If you are switching to the new tablet, check the equivalent dose with your doctor and pharmacist. Never combine tablets to reach a higher dose.

How to take the pill correctly

The way you take the pill is part of the treatment itself. According to the FDA prescribing information, the instructions are:

In the morning, on an empty stomach.
With only a little water, up to 120 ml.
Swallow the tablet whole, without splitting or chewing it.
Wait at least 30 minutes before eating, drinking or taking other medications.

You take the starting dose for 30 days, and it does not control blood sugar. After that, you move to the maintenance dose. If needed, the doctor raises the dose after at least another 30 days.

Side effects and safety in Rybelsus treatment

The common side effects involve the digestive system: nausea, diarrhea, constipation and a feeling of fullness. In most cases they are mild to moderate and pass. For example, in PIONEER 1, 2.3% to 7.4% of patients on the pill stopped treatment, compared with 2.2% on placebo.

In addition, there are rare risks shared by the whole GLP-1 family: pancreatitis and gallstones. People who have had medullary thyroid cancer, or whose family member has had it, must not use the drug. Moreover, the pill slows stomach emptying and may affect the absorption of other drugs. That is why it is important to tell your doctor about every medication you take. A broad review of side effects appears in my article on Wegovy side effects.

Infographic: Rybelsus treatment - trials, doses and how to take it

Who Rybelsus treatment suits best

Rybelsus treatment is especially suitable for people with type 2 diabetes who do not want injections. It also suits people at high cardiovascular risk, thanks to the SOUL results. People who fear needles or struggle with an injection pen will find it a convenient alternative, too.

On the other hand, the pill requires daily discipline. People who find it hard to wait half an hour before their morning coffee may lose some of its effectiveness. In such cases, a weekly injection is much more convenient. And if you have already chosen an injection and want to switch to a pill, read about switching from an injection to a pill.

Combined treatment: the drug is only part of the plan

No pill replaces lifestyle change. The best results come with nutritional counseling, regular physical activity and good sleep. At our clinic, we also work on eating patterns and offer emotional support. We also measure success over time, so sticking with treatment matters as much as choosing the drug.

Bottom line on Rybelsus treatment

Rybelsus was the first pill to bring semaglutide to diabetes care. Today it also protects the heart, and it comes in a smaller, more efficient tablet. Ultimately, Rybelsus treatment is best suited to people with diabetes who prefer a pill. For significant weight loss, there are now dedicated options. You and your doctor make the right decision together, based on your goals and health. You can find more on Rybelsus in diabetes in my article on what happens when diabetes treatment moves to a pill.

This article is general information and does not replace personal medical advice.